Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
Abstract Background Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. Methods We pooled data from 13 E...
Saved in:
| Published in | JNCI : Journal of the National Cancer Institute Vol. 110; no. 6; pp. 649 - 660 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Oxford University Press
01.06.2018
Oxford University Press (OUP) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0027-8874 1460-2105 1460-2105 |
| DOI | 10.1093/jnci/djx235 |
Cover
| Abstract | Abstract
Background
Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.
Methods
We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.
Results
Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.
Conclusions
For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. |
|---|---|
| AbstractList | Abstract
Background
Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.
Methods
We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.
Results
Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.
Conclusions
For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.BackgroundChildhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.MethodsWe pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.ResultsOverall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.ConclusionsFor the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma. For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. Background Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. Methods We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Results Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma. Conclusions For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Results: Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma. Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors andhealth care providers. Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer. Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Results: Overall, 301 STS developed compared with 19 expected (SIR ¼ 15.7, 95% confidence interval [CI] ¼ 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR ¼ 40.6, 95% CI ¼ 29.6 to 54.3), leiomyosarcomas (SIR ¼ 29.9, 95% CI ¼ 23.7 to 37.2), and fibromatous neoplasms (SIR ¼ 12.3, 95% CI ¼ 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR ¼ 80.5, 95% CI ¼ 48.4 to 125.7), Hodgkin lymphoma (SIR ¼ 81.3, 95% CI ¼ 35.1 to 160.1), and Wilms tumor (SIR ¼ 76.0, 95% CI ¼ 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR ¼ 342.9, 95% CI ¼ 245.0 to 466.9) and Wilms tumor (SIR ¼ 74.2, 95% CI ¼ 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 personyears), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI ¼ 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma. Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers. |
| Author | de Vathaire, Florent Hawkins, Mike M Bautz, Andrea Garwicz, Stanislaw Winther, Jeanette F Hjorth, Lars Terenziani, Monica Kaatsch, Peter Haddy, Nadia Winter, David L Allodji, Rodrigue S Bárdi, Edit Fidler, Miranda M Gudmundsdottir, Thorgerdur Kremer, Leontien C Skinner, Roderick Kuehni, Claudia E Guha, Joyeeta Byrne, Julianne Lähteenmäki, Päivi Bagnasco, Francesca Haupt, Riccardo Linge, Helena Zaletel, Lorna Zadravec Alessi, Daniela Feijen, Elizabeth A M Jakab, Zsuzsanna Jankovic, Momcilo Ronckers, Cecile M Teepen, Jop C Grabow, Desiree Kaiser, Melanie Kuonen, Rahel Wiebe, Thomas Reulen, Raoul C Sacerdote, Carlotta Øfstaas, Hilde Wesenberg, Finn Bright, Chloe J Vu-Bezin, Giao |
| AuthorAffiliation | 18 Department of Paediatrics, University Children's Hospital of Bern, University of Bern, Bern, Switzerland 12 Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark 16 Foundation MBBM, Hemato-Oncology Center, University of Milano-Bicocca, Monza, Italy 5 Hungarian Childhood Cancer Registry, Semmelweis University, Budapest, Hungary 22 Norwegian Cancer Registry and Department of Pediatric Medicine, Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway 4 Epidemiology and Biostatistics Section, Gaslini Children Hospital, Genova, Italy 20 Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK 24 Institute of Oncology, Ljubljana, Slovenia 9 Boyne Research Institute, Drogheda, Ireland 10 Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands 14 |
| AuthorAffiliation_xml | – name: 22 Norwegian Cancer Registry and Department of Pediatric Medicine, Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway – name: 12 Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark – name: 23 Department of Pediatric and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland – name: 15 Childreńs Hospital, Landspitali University Hospital, Reykjavik, Iceland – name: 16 Foundation MBBM, Hemato-Oncology Center, University of Milano-Bicocca, Monza, Italy – name: 19 Norwegian National Advisory Unit on Solid Tumors in Children, Oslo, Norway – name: 3 Cancer and Radiation Team, U1018 INSERM, Gustave Roussy, Villejuif, France – name: 18 Department of Paediatrics, University Children's Hospital of Bern, University of Bern, Bern, Switzerland – name: 20 Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK – name: 25 Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands – name: 6 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary – name: 8 Danish Cancer Society Research Center, Survivorship Unit, Copenhagen, Denmark – name: 11 Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden – name: 14 German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany – name: 17 Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland – name: 7 Kepler Universitätsklinikum, Linz, Austria – name: 5 Hungarian Childhood Cancer Registry, Semmelweis University, Budapest, Hungary – name: 10 Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands – name: 2 Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOU Città della Salute e della Scienza di Torino, Torino, Italy – name: 4 Epidemiology and Biostatistics Section, Gaslini Children Hospital, Genova, Italy – name: 21 Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy – name: 24 Institute of Oncology, Ljubljana, Slovenia – name: 1 Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – name: 9 Boyne Research Institute, Drogheda, Ireland |
| Author_xml | – sequence: 1 givenname: Chloe J surname: Bright fullname: Bright, Chloe J organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – sequence: 2 givenname: Mike M surname: Hawkins fullname: Hawkins, Mike M organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – sequence: 3 givenname: David L surname: Winter fullname: Winter, David L organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – sequence: 4 givenname: Daniela surname: Alessi fullname: Alessi, Daniela organization: Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOU Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 5 givenname: Rodrigue S surname: Allodji fullname: Allodji, Rodrigue S organization: Cancer and Radiation Team, U1018 INSERM, Gustave Roussy, Villejuif, France – sequence: 6 givenname: Francesca surname: Bagnasco fullname: Bagnasco, Francesca organization: Epidemiology and Biostatistics Section, Gaslini Children Hospital, Genova, Italy – sequence: 7 givenname: Edit surname: Bárdi fullname: Bárdi, Edit organization: nd Department of Pediatrics, Semmelweis University, Budapest, Hungary – sequence: 8 givenname: Andrea surname: Bautz fullname: Bautz, Andrea organization: Danish Cancer Society Research Center, Survivorship Unit, Copenhagen, Denmark – sequence: 9 givenname: Julianne surname: Byrne fullname: Byrne, Julianne organization: Boyne Research Institute, Drogheda, Ireland – sequence: 10 givenname: Elizabeth A M surname: Feijen fullname: Feijen, Elizabeth A M organization: Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 11 givenname: Miranda M surname: Fidler fullname: Fidler, Miranda M organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – sequence: 12 givenname: Stanislaw surname: Garwicz fullname: Garwicz, Stanislaw organization: Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden – sequence: 13 givenname: Desiree surname: Grabow fullname: Grabow, Desiree organization: German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany – sequence: 14 givenname: Thorgerdur surname: Gudmundsdottir fullname: Gudmundsdottir, Thorgerdur organization: Danish Cancer Society Research Center, Survivorship Unit, Copenhagen, Denmark – sequence: 15 givenname: Joyeeta surname: Guha fullname: Guha, Joyeeta organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK – sequence: 16 givenname: Nadia surname: Haddy fullname: Haddy, Nadia organization: Cancer and Radiation Team, U1018 INSERM, Gustave Roussy, Villejuif, France – sequence: 17 givenname: Momcilo surname: Jankovic fullname: Jankovic, Momcilo organization: Foundation MBBM, Hemato-Oncology Center, University of Milano-Bicocca, Monza, Italy – sequence: 18 givenname: Peter surname: Kaatsch fullname: Kaatsch, Peter organization: German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany – sequence: 19 givenname: Melanie surname: Kaiser fullname: Kaiser, Melanie organization: German Childhood Cancer Registry (GCCR), Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Mainz, Germany – sequence: 20 givenname: Claudia E surname: Kuehni fullname: Kuehni, Claudia E organization: Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland – sequence: 21 givenname: Helena surname: Linge fullname: Linge, Helena organization: Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden – sequence: 22 givenname: Hilde surname: Øfstaas fullname: Øfstaas, Hilde organization: Norwegian National Advisory Unit on Solid Tumors in Children, Oslo, Norway – sequence: 23 givenname: Cecile M surname: Ronckers fullname: Ronckers, Cecile M organization: Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 24 givenname: Roderick surname: Skinner fullname: Skinner, Roderick organization: Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, and Northern Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK – sequence: 25 givenname: Jop C surname: Teepen fullname: Teepen, Jop C organization: Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 26 givenname: Monica surname: Terenziani fullname: Terenziani, Monica organization: Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy – sequence: 27 givenname: Giao surname: Vu-Bezin fullname: Vu-Bezin, Giao organization: Cancer and Radiation Team, U1018 INSERM, Gustave Roussy, Villejuif, France – sequence: 28 givenname: Finn surname: Wesenberg fullname: Wesenberg, Finn organization: Norwegian Cancer Registry and Department of Pediatric Medicine, Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway – sequence: 29 givenname: Thomas surname: Wiebe fullname: Wiebe, Thomas organization: Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden – sequence: 30 givenname: Carlotta surname: Sacerdote fullname: Sacerdote, Carlotta organization: Childhood Cancer Registry of Piedmont, Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and AOU Città della Salute e della Scienza di Torino, Torino, Italy – sequence: 31 givenname: Zsuzsanna surname: Jakab fullname: Jakab, Zsuzsanna organization: Hungarian Childhood Cancer Registry, Semmelweis University, Budapest, Hungary – sequence: 32 givenname: Riccardo surname: Haupt fullname: Haupt, Riccardo organization: Epidemiology and Biostatistics Section, Gaslini Children Hospital, Genova, Italy – sequence: 33 givenname: Päivi surname: Lähteenmäki fullname: Lähteenmäki, Päivi organization: Department of Pediatric and Adolescent Medicine, Turku University and Turku University Hospital, Turku, Finland – sequence: 34 givenname: Lorna Zadravec surname: Zaletel fullname: Zaletel, Lorna Zadravec organization: Institute of Oncology, Ljubljana, Slovenia – sequence: 35 givenname: Rahel surname: Kuonen fullname: Kuonen, Rahel – sequence: 36 givenname: Jeanette F surname: Winther fullname: Winther, Jeanette F organization: Danish Cancer Society Research Center, Survivorship Unit, Copenhagen, Denmark – sequence: 37 givenname: Florent surname: de Vathaire fullname: de Vathaire, Florent organization: Cancer and Radiation Team, U1018 INSERM, Gustave Roussy, Villejuif, France – sequence: 38 givenname: Leontien C surname: Kremer fullname: Kremer, Leontien C organization: Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, Amsterdam, the Netherlands – sequence: 39 givenname: Lars surname: Hjorth fullname: Hjorth, Lars organization: Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Pediatrics, Lund, Sweden – sequence: 40 givenname: Raoul C surname: Reulen fullname: Reulen, Raoul C email: r.c.reulen@bham.ac.uk organization: Center for Childhood Cancer Survivor Studies, Institute of Applied Health Research, Robert Aitken Building, University of Birmingham, Birmingham, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29165710$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-04439772$$DView record in HAL |
| BookMark | eNp9ks2P0zAQxSO0iP2AE3fICSFBWNtJnPqCVFW7LFIlJLoc4DKa2pOtS2oXOynw3-OSLWJXCF988O-9Nx690-zIeUdZ9pSzN5yp8nzttD036x-irB9kJ7ySrBCc1UfZCWOiKSaTpjrOTmNcs3SUqB5lx0JxWTecnWRfPtr4NfdtvvBtX1zbGAfKFxi032A-3Xh3k0uVJ8_80u6o-EwY8sUQdnbnQ9zrZivbmZX3Jp-h0xRy6_KLIfgtPc4etthFenJ7n2WfLi-uZ1fF_MO797PpvNBSqL4wSurSLJfEjOSmoro2vFVKiaaVXKFW2LCKGURjDBGxRinkssWqkrUQpMuzDEff-J22wxK2wW4w_ASPFrY-9NhBoJgG1yvoBogEieqsxt56F6FtETUKhHY5QaioJFgqo4C3TWukRiUEpoy3Y0aSbshocn1Ivnei7rw4u4IbvwPJWM24SgavR4PVPdnVdA7WRQobYFVVqqYRO57w5yOug429deB8QOBsUgtIW2vqRLy8nSj4bwPFHjY2auo6dOSHCFzJppKiZGVCn_09_J_4QwsSwA9pPsZALWjb_15P-ovtUi7smwb7psHYtKR5dU9zsP03_WKk_bD9L_gLbZrksQ |
| CitedBy_id | crossref_primary_10_1200_JCO_19_01096 crossref_primary_10_1200_JCO_23_00452 crossref_primary_10_1002_cam4_5519 crossref_primary_10_3390_cancers12102905 crossref_primary_10_5812_ijp_145185 crossref_primary_10_1038_s41416_022_02016_w crossref_primary_10_3390_ijerph18083918 crossref_primary_10_1002_pbc_30258 crossref_primary_10_1007_s00761_018_0449_1 crossref_primary_10_1038_s41416_024_02577_y crossref_primary_10_1016_j_pcl_2020_07_002 crossref_primary_10_3390_cancers12092717 crossref_primary_10_3390_cancers13205064 crossref_primary_10_2478_raon_2022_0027 crossref_primary_10_1016_j_ejca_2019_05_013 crossref_primary_10_1007_s10552_019_01204_z crossref_primary_10_1002_ijc_33817 crossref_primary_10_1001_jama_2023_16875 crossref_primary_10_1016_j_pcl_2020_07_006 crossref_primary_10_18203_issn_2454_2156_IntJSciRep20243495 crossref_primary_10_1016_j_ejca_2022_01_001 crossref_primary_10_1007_s11864_024_01192_6 crossref_primary_10_1093_jjco_hyy102 crossref_primary_10_1016_j_radonc_2019_03_015 crossref_primary_10_1186_s12964_022_00930_3 crossref_primary_10_1002_cncr_31807 crossref_primary_10_1016_j_ejcped_2024_100155 crossref_primary_10_3390_cancers15153932 crossref_primary_10_1136_gutjnl_2020_322237 crossref_primary_10_1007_s10654_018_0370_3 crossref_primary_10_1016_j_canep_2020_101733 crossref_primary_10_1016_j_canep_2020_101779 crossref_primary_10_1093_jncics_pkz043 crossref_primary_10_32635_2176_9745_RBC_2024v70n1_4592 |
| Cites_doi | 10.1093/jnci/djp104 10.1016/j.ejca.2006.10.004 10.1016/j.ijrobp.2011.11.022 10.1186/2045-3329-2-18 10.1038/sj.bjc.6603908 10.1093/jnci/djn394 10.1001/jama.1997.03550150066037 10.1002/cncr.20910 10.1001/jama.2011.747 10.1186/2045-3329-2-15 10.1002/sim.1597 10.1093/jnci/djq238 10.1177/1536867X0400400201 10.1038/bjc.2013.228 10.3389/fonc.2014.00324 10.1093/jnci/djk002 10.1002/ijc.22827 10.1200/JCO.2005.03.8349 10.1016/j.ejca.2015.04.002 10.1200/JCO.2013.54.7844 10.1093/jnci/djk052 10.1002/ijc.20002 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6 10.5694/j.1326-5377.2010.tb03902.x 10.1016/S1470-2045(13)70548-5 10.1002/cncr.21773 |
| ContentType | Journal Article |
| Copyright | The Author 2017. Published by Oxford University Press. 2017 info:eu-repo/semantics/openAccess Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author 2017. Published by Oxford University Press. 2017 – notice: info:eu-repo/semantics/openAccess – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| CorporateAuthor | The PanCareSurFup Consortium PanCareSurFup Consortium Late effects after childhood cancer treatment Pediatrik, Lund Section V Institutionen för kliniska vetenskaper, Lund Infektionsmedicin Lunds universitet Sena effekter efter barncancerbehandling Lund University Sektion V Sektion III Department of Clinical Sciences, Lund Mass Spectrometry Faculty of Medicine Masspektrometri SEBRA Sepsis and Bacterial Resistance Alliance Paediatrics (Lund) Section III Infection Medicine (BMC) Medicinska fakulteten BioMS |
| CorporateAuthor_xml | – name: The PanCareSurFup Consortium – name: PanCareSurFup Consortium – name: Faculty of Medicine – name: Medicinska fakulteten – name: Mass Spectrometry – name: Sektion III – name: BioMS – name: Institutionen för kliniska vetenskaper, Lund – name: Lunds universitet – name: Masspektrometri – name: Department of Clinical Sciences, Lund – name: Paediatrics (Lund) – name: Late effects after childhood cancer treatment – name: Lund University – name: Section III – name: Sektion V – name: Pediatrik, Lund – name: Section V – name: Sena effekter efter barncancerbehandling – name: Infection Medicine (BMC) – name: Infektionsmedicin – name: SEBRA Sepsis and Bacterial Resistance Alliance |
| DBID | TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 3HK 1XC VOOES 5PM ADTPV AGCHP AOWAS D8T D95 ZZAVC |
| DOI | 10.1093/jnci/djx235 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic NORA - Norwegian Open Research Archives Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) SwePub SWEPUB Lunds universitet full text SwePub Articles SWEPUB Freely available online SWEPUB Lunds universitet SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2105 |
| EndPage | 660 |
| ExternalDocumentID | oai_portal_research_lu_se_publications_ffaaca2a_fb8a_4e3e_b9d9_1f7fd6ca922a PMC6005019 oai_HAL_inserm_04439772v1 10852_62975 29165710 10_1093_jnci_djx235 10.1093/jnci/djx235 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 08P 0R~ 1TH 29L 2WC 354 4.4 482 48X 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAHTB AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP AAWTL ABCQX ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPPZ ABPTD ABQLI ABQNK ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENZO AEPUE AETBJ AEWNT AFAZI AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGKEF AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG BAWUL BAYMD BCRHZ BEYMZ BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F8P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NU- OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RHF RNS ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TOX TR2 TWZ UDS UPT VVN W8F WH7 WOQ X7H YAYTL YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 AAYXX ABDFA ABEJV ABGNP ABVGC ADNBA AEMQT AFYAG AGORE AHMMS AJBYB AJNCP ALXQX CITATION CGR CUY CVF ECM EIF NPM 7X8 -DD .55 .GJ 08R 186 2QL 3HK 3O- 53G 6.Y 69O 8WZ A6W AABJS AABMN AAESY AAGKA AAIYJ AAKAS AANRK AAPBV AAPGJ AAQQT AAUGY AAWDT ABEFU ABPMR ABPTK ABQTQ ABSAR ABSMQ ACFRR ACIMA ACPQN ADEIU ADMTO ADORX ADQLU ADZCM AEKPW AETEA AFCHL AFUVZ AFXEN AGKRT AGNAY AGVJH AI. AIKOY AIMBJ AQDSO AQKUS ASMCH ASPBG ATTQO AVWKF AWCFO AXUDD AZFZN AZQFJ BGYMP BHONS BKOMP BYORX BZKNY CAG CASEJ COF DPORF DPPUQ EIHJH EJD F3I FA8 FEDTE GOZPB GRPMH J5H K78 KC5 LXL LXN LXY MBLQV MVM NTWIH NVLIB O0~ O~Y PB- PQEST QBD RNI RZF RZO UMP VH1 X7M XJT Y6R YHZ ZA5 ~X8 1XC VOOES 5PM ABNGD ACUKT ACVCV ACZBC ADTPV ADXHL AEHUL AFFQV AFSHK AGCHP AGMDO AGQPQ AHGBF AJDVS AOWAS APJGH AVNTJ D8T D95 HVGLF OBFPC YR5 ZZAVC |
| ID | FETCH-LOGICAL-c629t-d96c3dbbe0d61d4e55d1f99927f619ac9a7040daadddeee0799a16fa446522ec3 |
| IEDL.DBID | TOX |
| ISSN | 0027-8874 1460-2105 |
| IngestDate | Wed Sep 10 00:15:18 EDT 2025 Thu Aug 21 18:33:57 EDT 2025 Fri Sep 12 12:40:57 EDT 2025 Sat Apr 29 05:43:00 EDT 2023 Sun Sep 28 09:14:24 EDT 2025 Mon Jul 21 06:05:50 EDT 2025 Tue Jul 01 02:54:29 EDT 2025 Thu Apr 24 23:05:08 EDT 2025 Wed Sep 11 04:51:44 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/4.0 Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c629t-d96c3dbbe0d61d4e55d1f99927f619ac9a7040daadddeee0799a16fa446522ec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC6005019 See the Notes section for the full list of authors and affiliations. |
| OpenAccessLink | https://dx.doi.org/10.1093/jnci/djx235 |
| PMID | 29165710 |
| PQID | 1967462303 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | swepub_primary_oai_portal_research_lu_se_publications_ffaaca2a_fb8a_4e3e_b9d9_1f7fd6ca922a pubmedcentral_primary_oai_pubmedcentral_nih_gov_6005019 hal_primary_oai_HAL_inserm_04439772v1 cristin_nora_10852_62975 proquest_miscellaneous_1967462303 pubmed_primary_29165710 crossref_citationtrail_10_1093_jnci_djx235 crossref_primary_10_1093_jnci_djx235 oup_primary_10_1093_jnci_djx235 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-06-01 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: 2018-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JNCI : Journal of the National Cancer Institute |
| PublicationTitleAlternate | J Natl Cancer Inst |
| PublicationYear | 2018 |
| Publisher | Oxford University Press Oxford University Press (OUP) |
| Publisher_xml | – name: Oxford University Press – name: Oxford University Press (OUP) |
| References | Ferlay ( key 20180618194735_djx235-B20) 2008 Wong ( key 20180618194735_djx235-B18) 1997; 278 Barr ( key 20180618194735_djx235-B21) 2006; 106 Kleinerman ( key 20180618194735_djx235-B14) 2012; 2 Inskip ( key 20180618194735_djx235-B6) 2007; 121 Olsen ( key 20180618194735_djx235-B4) 2009; 101 Covillo ( key 20180618194735_djx235-B25) 2004 Esteve ( key 20180618194735_djx235-B26) 1994 Cardous-Ubbink ( key 20180618194735_djx235-B7) 2007; 43 Menu-Branthomme ( key 20180618194735_djx235-B11) 2004; 110 Berrington de Gonzalez ( key 20180618194735_djx235-B13) 2012; 2 Henderson ( key 20180618194735_djx235-B9) 2007; 99 Office of National Statistics ( key 20180618194735_djx235-B22) 2006 ( key 20180618194735_djx235-B23) 2011 Jenkinson ( key 20180618194735_djx235-B10) 2007; 97 Hjorth ( key 20180618194735_djx235-B2) 2015; 51 Gatta ( key 20180618194735_djx235-B1) 2014; 15 Friedman ( key 20180618194735_djx235-B5) 2010; 102 Reulen ( key 20180618194735_djx235-B3) 2011; 305 Sharif ( key 20180618194735_djx235-B29) 2006; 24 Ederer ( key 20180618194735_djx235-B27) 1959 MacCarthy ( key 20180618194735_djx235-B28) 2013; 108 Steliarova-Foucher ( key 20180618194735_djx235-B19) 2005; 103 Wilson ( key 20180618194735_djx235-B8) 2010; 193 Dickman ( key 20180618194735_djx235-B24) 2004; 23 Henderson ( key 20180618194735_djx235-B12) 2012; 84 Marees ( key 20180618194735_djx235-B17) 2008; 100 Kahn ( key 20180618194735_djx235-B30) 2014; 4 Wong ( key 20180618194735_djx235-B16) 2014; 32 Ducatman ( key 20180618194735_djx235-B31) 1986; 57 Kleinerman ( key 20180618194735_djx235-B15) 2007; 99 |
| References_xml | – volume: 101 start-page: 806 issue: 11 year: 2009 ident: key 20180618194735_djx235-B4 article-title: Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djp104 – volume: 43 start-page: 351 issue: 2 year: 2007 ident: key 20180618194735_djx235-B7 article-title: Risk of second malignancies in long-term survivors of childhood cancer publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2006.10.004 – year: 2008 ident: key 20180618194735_djx235-B20 – volume: 84 start-page: 224 issue: 1 year: 2012 ident: key 20180618194735_djx235-B12 article-title: Risk factors associated with secondary sarcomas in childhood cancer survivors: A report from the childhood cancer survivor study publication-title: Int J Radiat Oncol Biol Phys. doi: 10.1016/j.ijrobp.2011.11.022 – volume: 2 start-page: 18–18 year: 2012 ident: key 20180618194735_djx235-B13 article-title: Sarcoma risk after radiation exposure publication-title: Clin Sarcoma Res. doi: 10.1186/2045-3329-2-18 – volume: 97 start-page: 695 issue: 5 year: 2007 ident: key 20180618194735_djx235-B10 article-title: A study of soft tissue sarcomas after childhood cancer in Britain publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6603908 – year: 1959 ident: key 20180618194735_djx235-B27 – volume: 100 start-page: 1771 issue: 24 year: 2008 ident: key 20180618194735_djx235-B17 article-title: Risk of second malignancies in survivors of retinoblastoma: More than 40 years of follow-up publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djn394 – volume: 278 start-page: 1262 issue: 15 year: 1997 ident: key 20180618194735_djx235-B18 article-title: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk publication-title: JAMA. doi: 10.1001/jama.1997.03550150066037 – volume: 103 start-page: 1457 issue: 7 year: 2005 ident: key 20180618194735_djx235-B19 article-title: International Classification of Childhood Cancer, third edition publication-title: Cancer. doi: 10.1002/cncr.20910 – volume: 305 start-page: 2311 issue: 22 year: 2011 ident: key 20180618194735_djx235-B3 article-title: Long-term risks of subsequent primary neoplasms among survivors of childhood cancer publication-title: JAMA. doi: 10.1001/jama.2011.747 – volume: 2 start-page: 15 issue: 1 year: 2012 ident: key 20180618194735_djx235-B14 article-title: Sarcomas in hereditary retinoblastoma publication-title: Clin Sarcoma Res. doi: 10.1186/2045-3329-2-15 – volume: 23 start-page: 51 issue: 1 year: 2004 ident: key 20180618194735_djx235-B24 article-title: Regression models for relative survival publication-title: Stat Med. doi: 10.1002/sim.1597 – volume: 102 start-page: 1083 issue: 14 year: 2010 ident: key 20180618194735_djx235-B5 article-title: Subsequent neoplasms in 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djq238 – start-page: 103 year: 2004 ident: key 20180618194735_djx235-B25 article-title: Cumulative incidence estimation in the presence of competing risks publication-title: Stata J doi: 10.1177/1536867X0400400201 – volume: 108 start-page: 2455 issue: 12 year: 2013 ident: key 20180618194735_djx235-B28 article-title: Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004 publication-title: Br J Cancer. doi: 10.1038/bjc.2013.228 – year: 2011 ident: key 20180618194735_djx235-B23 – volume: 4 start-page: 324 year: 2014 ident: key 20180618194735_djx235-B30 article-title: Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors publication-title: Front Oncol. doi: 10.3389/fonc.2014.00324 – volume-title: Cancer Statistics Registrations - Series MB1 year: 2006 ident: key 20180618194735_djx235-B22 – volume-title: Statistical Methods in Cancer Research. Volume IV: Descriptive Epidemiology year: 1994 ident: key 20180618194735_djx235-B26 – volume: 99 start-page: 24 issue: 1 year: 2007 ident: key 20180618194735_djx235-B15 article-title: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djk002 – volume: 121 start-page: 2233 issue: 10 year: 2007 ident: key 20180618194735_djx235-B6 article-title: New malignancies following childhood cancer in the United States, 1973-2002 publication-title: Int J Cancer. doi: 10.1002/ijc.22827 – volume: 24 start-page: 2570 issue: 16 year: 2006 ident: key 20180618194735_djx235-B29 article-title: Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy publication-title: J Clin Oncol. doi: 10.1200/JCO.2005.03.8349 – volume: 51 start-page: 1203 issue: 10 year: 2015 ident: key 20180618194735_djx235-B2 article-title: Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2015.04.002 – volume: 32 start-page: 3284 issue: 29 year: 2014 ident: key 20180618194735_djx235-B16 article-title: Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy publication-title: J Clin Oncol. doi: 10.1200/JCO.2013.54.7844 – volume: 99 start-page: 300 issue: 4 year: 2007 ident: key 20180618194735_djx235-B9 article-title: Secondary sarcomas in childhood cancer survivors: A report from the Childhood Cancer Survivor Study publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djk052 – volume: 110 start-page: 87 issue: 1 year: 2004 ident: key 20180618194735_djx235-B11 article-title: Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood publication-title: Int J Cancer. doi: 10.1002/ijc.20002 – volume: 57 start-page: 2006 issue: 10 year: 1986 ident: key 20180618194735_djx235-B31 article-title: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases publication-title: Cancer. doi: 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6 – volume: 193 start-page: 258 issue: 5 year: 2010 ident: key 20180618194735_djx235-B8 article-title: Late mortality and second cancers in an Australian cohort of childhood cancer survivors publication-title: Med J Aust. doi: 10.5694/j.1326-5377.2010.tb03902.x – volume: 15 start-page: 35 issue: 1 year: 2014 ident: key 20180618194735_djx235-B1 article-title: Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—a population-based study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70548-5 – volume: 106 start-page: 1425 issue: 7 year: 2006 ident: key 20180618194735_djx235-B21 article-title: Classification schemes for tumors diagnosed in adolescents and young adults publication-title: Cancer. doi: 10.1002/cncr.21773 |
| SSID | ssj0000924 |
| Score | 2.456468 |
| Snippet | Abstract
Background
Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological... Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We... Background Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are... Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are... |
| SourceID | swepub pubmedcentral hal cristin proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 649 |
| SubjectTerms | Adolescent Adult Cancer and Oncology Cancer och onkologi Cancer Survivors - statistics & numerical data Child Child, Preschool Clinical Medicine Cohort Studies Europe - epidemiology Female Follow-Up Studies Humans Incidence Infant Infant, Newborn Klinisk medicin Life Sciences Male Medical and Health Sciences Medicin och hälsovetenskap Middle Aged Neoplasms, Second Primary - epidemiology Registries Risk Factors Santé publique et épidémiologie Sarcoma - epidemiology Soft Tissue Neoplasms - epidemiology Time Factors Young Adult |
| Title | Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29165710 https://www.proquest.com/docview/1967462303 http://hdl.handle.net/10852/62975 https://inserm.hal.science/inserm-04439772 https://pubmed.ncbi.nlm.nih.gov/PMC6005019 |
| Volume | 110 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Jb9QwFLagB8QFsTcsxUjlghQ1sR07Po4qRsNSkJipNPRiOV406eJUs1T8fJ6TdGiggnNsK_Fb_L289z4jtF_6whpGdRrRfsrKwqdSuiKl1lHrC6eFjRndo698csw-zYt5XyC7uiWFL-nBaTD1gT39SWjsJYfjN6rz7Nv8t8OVpCdbBodbCta34f0xFwCuae0mDI6gu4tYADlobruBMf8ulRwQiraH0PghetCjRzzqxP0I3XHhMbp31OfHn6CT7_XqDDceT8G7prN2U_EUdLm50HgU7xXCXGLGMzwGL5f-ADXH0w14i6tmuYrztkzH-DCqwxLXAXc_7J-i4_GH2eEk7W9PSA0ncp1ayQ21VeUyy3PLXFHY3AMcJMJD0KSN1AIM2GpwcNY5lwkpdc69jgxqhDhDn6Gd0AS3i7CQpMoohILGEqZzW3LBjCPU56JiRIsE7fZbqwIobiQdLYjisWk3Qe-v91qZnnU8Xn5xrrrsN1VRRKoTUYL2t4MvO7KN24e9A6FtR0SC7Mnoi6oDGO2FyljEWIJc5Ql6A2L990pvr0WuwKxirkQH12xWChyTYAANM5qg550KbBciAKkLQGYJEgPlGLzR8EmoFy11N498O7lM0EmnRsMpbcClepanhTrfqJVTlzd-3yrvtTaaaOWrUivmqFOVtFLlXnjLjZaE6Bf__eyX6D7gvrKreHuFdtbLjXsN2Gpd7UFU8fHzXmtfvwCRBiV3 |
| linkProvider | Oxford University Press |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+Soft-Tissue+Sarcoma+Among+69+460+Five-Year+Survivors+of+Childhood+Cancer+in+Europe&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Bright%2C+Chloe+J&rft.au=Hawkins%2C+Mike+M&rft.au=Winter%2C+David+L&rft.au=Alessi%2C+Daniela&rft.date=2018-06-01&rft.pub=Oxford+University+Press&rft.issn=0027-8874&rft.eissn=1460-2105&rft.volume=110&rft.issue=6&rft.spage=649&rft.epage=660&rft_id=info:doi/10.1093%2Fjnci%2Fdjx235&rft_id=info%3Apmid%2F29165710&rft.externalDocID=PMC6005019 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0027-8874&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0027-8874&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0027-8874&client=summon |